Skip to main content
ORASURE TECHNOLOGIES INC logo

ORASURE TECHNOLOGIES INC — Investor Relations & Filings

Ticker · OSUR ISIN · US68554V1089 LEI · 529900GNNJPNM4XHXQ77 US Manufacturing
Open in API
Filings indexed 1,018 across all filing types
Latest filing 2025-04-04 Major Shareholding Noti…
Country US United States of America
Listing US OSUR

About ORASURE TECHNOLOGIES INC

https://www.orasure.com/

OraSure Technologies, Inc. develops, manufactures, and distributes diagnostic products and sample collection tools. The company specializes in non-invasive technologies, particularly oral fluid-based solutions, to decentralize diagnostics and improve healthcare access. Its portfolio includes point-of-care and over-the-counter rapid tests for infectious diseases such as HIV and COVID-19. A notable achievement is the development of the first over-the-counter at-home HIV test. Through its subsidiaries, OraSure also provides sample management solutions for the collection of biological samples used in genomic, metabolomic, and microbiome research, serving healthcare providers, researchers, and consumers.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2025
Major Shareholding Notification
2025-04-04 English
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2025-03-27 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated March 24, 2025, by OraSure Technologies, Inc. The key content is the announcement of a new stock repurchase program authorized by the board of directors, replacing a previous repurchase program. The document includes a press release about the stock repurchase plan and mentions that details of repurchases will be reported in periodic filings (10-Q and 10-K). The document is primarily an announcement of a capital activity (stock repurchase program) and does not contain financial statements or detailed financial analysis itself. The length is about 5408 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2025-03-24 English
10-K
Annual Report FY 2024
2025-03-07 English
8-K/A
Regulatory Filings Classification · 95% confidence The document is a Form 8-K/A (Amendment No.1) filed with the SEC, which is a Current Report pursuant to the Securities Exchange Act of 1934. It amends a previously filed Form 8-K to provide additional financial information related to the acquisition of Sherlock Biosciences, Inc. The document includes references to audited financial statements and pro forma financial information as exhibits, but the main body is an amendment report rather than the full financial statements themselves. The document is a regulatory filing updating prior disclosures with supplemental financial data. Therefore, it fits best under the category of Regulatory Filings (RNS), as it is not a full annual or quarterly report, nor a standalone audit report, but an amendment to a current report providing additional information.
2025-03-07 English
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2025-03-04 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.